Investor Update

Basel, 20 September 2019

Chugai obtained approval for additional indication and formulation for Tecentriq in PD-L1-positive triple negative breast cancer

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.